{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:16:32Z","timestamp":1784157392870,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03163-1","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:32:13Z","timestamp":1743370333000},"page":"2500-2512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population"],"prefix":"10.1007","volume":"42","author":[{"given":"Eric","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Champaloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mena","family":"Boules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sanchez Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"3163_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1053\/j.gastro.2023.03.214","volume":"164","author":"L Chang","year":"2023","unstructured":"Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. 2023;164:1086\u2013106.","journal-title":"Gastroenterology"},{"key":"3163_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.gastro.2022.04.016","volume":"163","author":"L Chang","year":"2022","unstructured":"Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology. 2022;163:118\u201336.","journal-title":"Gastroenterology"},{"key":"3163_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.14309\/ajg.0000000000001708","volume":"117","author":"LA Harris","year":"2022","unstructured":"Harris LA, Chang CH. Burden of constipation: looking beyond bowel movements. Off J Am Coll Gastroenterol ACG. 2022;117:S2\u20135.","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"3163_CR4","unstructured":"Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016."},{"key":"3163_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.dld.2013.03.016","volume":"45","author":"G Basilisco","year":"2013","unstructured":"Basilisco G, Coletta M. Chronic constipation: a critical review. Dig Liver Dis. 2013;45:886\u201393.","journal-title":"Dig Liver Dis"},{"key":"3163_CR6","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ajg.2015.67","volume":"110","author":"JJ Heidelbaugh","year":"2015","unstructured":"Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110:580\u20137.","journal-title":"Am J Gastroenterol"},{"key":"3163_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5056\/jnm17112","volume":"24","author":"ED Shah","year":"2018","unstructured":"Shah ED, Almario CV, Spiegel BMR, Chey WD. Lower and upper gastrointestinal symptoms differ between individuals with irritable bowel syndrome with constipation or chronic idiopathic constipation. J Neurogastroenterol Motil. 2018;24:299\u2013306.","journal-title":"J Neurogastroenterol Motil"},{"key":"3163_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.5056\/jnm16001","volume":"22","author":"MH Farzaei","year":"2016","unstructured":"Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22:558\u201374.","journal-title":"J Neurogastroenterol Motil"},{"key":"3163_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","volume":"150","author":"BE Lacy","year":"2016","unstructured":"Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393-407.e5.","journal-title":"Gastroenterology"},{"key":"3163_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3810\/pgm.2013.03.2640","volume":"125","author":"D Nellesen","year":"2013","unstructured":"Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW. Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade. Postgrad Med. 2013;125:40\u201350.","journal-title":"Postgrad Med"},{"key":"3163_CR11","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/s12325-017-0633-5","volume":"34","author":"LA Harris","year":"2017","unstructured":"Harris LA, Horn J, Kissous-Hunt M, Magnus L, Quigley EMM. The better understanding and recognition of the disconnects, experiences, and needs of patients with chronic idiopathic constipation (BURDEN-CIC) study: results of an online questionnaire. Adv Ther. 2017;34:2661\u201373.","journal-title":"Adv Ther"},{"key":"3163_CR12","first-page":"102","volume":"13","author":"M Kopczy\u0144ska","year":"2018","unstructured":"Kopczy\u0144ska M, Mokros \u0141, Pietras T, Ma\u0142ecka-Panas E. Quality of life and depression in patients with irritable bowel syndrome. Gastroenterol Rev\/Przegl\u0105d Gastroenterologiczny. 2018;13:102\u20138.","journal-title":"Gastroenterol Rev\/Przegl\u0105d Gastroenterologiczny"},{"key":"3163_CR13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s12325-018-0733-x","volume":"35","author":"EMM Quigley","year":"2018","unstructured":"Quigley EMM, Horn J, Kissous-Hunt M, Crozier RA, Harris LA. Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire. Adv Ther. 2018;35:967\u201380.","journal-title":"Adv Ther"},{"key":"3163_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2147\/CEG.S239205","volume":"13","author":"A Nag","year":"2020","unstructured":"Nag A, Martin SA, Mladsi D, Olayinka-Amao O, Purser M, Vekaria RM. The humanistic and economic burden of chronic idiopathic constipation in the USA: a systematic literature review. Clin Exp Gastroenterol. 2020;13:255\u201365.","journal-title":"Clin Exp Gastroenterol"},{"key":"3163_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","volume":"116","author":"BE Lacy","year":"2021","unstructured":"Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116:17\u201344.","journal-title":"Am J Gastroenterol"},{"key":"3163_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","volume":"155","author":"CJ Black","year":"2018","unstructured":"Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155:1753\u201363.","journal-title":"Gastroenterology"},{"key":"3163_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S2468-1253(19)30246-8","volume":"4","author":"P Luthra","year":"2019","unstructured":"Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:831\u201344.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3163_CR18","doi-asserted-by":"publisher","first-page":"238146832097841","DOI":"10.1177\/2381468320978417","volume":"6","author":"ED Shah","year":"2021","unstructured":"Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Pharmacologic, dietary, and psychological treatments for irritable bowel syndrome with constipation: cost utility analysis. MDM Policy & Practice. 2021;6:2381468320978417.","journal-title":"MDM Policy & Practice"},{"key":"3163_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12876-019-0985-1","volume":"19","author":"J Tack","year":"2019","unstructured":"Tack J, Stanghellini V, Mearin F, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19:69.","journal-title":"BMC Gastroenterol"},{"key":"3163_CR20","first-page":"382","volume":"20","author":"JA Doshi","year":"2014","unstructured":"Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm. 2014;20:382\u201390.","journal-title":"J Manag Care Spec Pharm"},{"key":"3163_CR21","first-page":"S581","volume":"107","author":"Q Cai","year":"2012","unstructured":"Cai Q, Buono J, Spalding W, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective cohort study in a large managed care population: 1459. Off J Am Coll Gastroenterol ACG. 2012;107:S581\u20132.","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"3163_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/archinte.163.8.929","volume":"163","author":"SA Leong","year":"2003","unstructured":"Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med. 2003;163:929\u201335.","journal-title":"Arch Intern Med"},{"key":"3163_CR23","first-page":"755","volume":"19","author":"D Nellesen","year":"2013","unstructured":"Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19:755\u201364.","journal-title":"J Manag Care Pharm"},{"key":"3163_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/13696998.2016.1253584","volume":"20","author":"LM Herrick","year":"2017","unstructured":"Herrick LM, Spalding WM, Saito YA, Moriarty J, Schleck C. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. J Med Econ. 2017;20:273\u20139.","journal-title":"J Med Econ"},{"key":"3163_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3111\/13696998.2013.860375","volume":"17","author":"Q Cai","year":"2014","unstructured":"Cai Q, Buono JL, Spalding WM, et al. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population. J Med Econ. 2014;17:148\u201358.","journal-title":"J Med Econ"},{"key":"3163_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3111\/13696998.2014.979291","volume":"18","author":"H Huang","year":"2015","unstructured":"Huang H, Taylor DCA, Carson RT, et al. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. J Med Econ. 2015;18:283\u201394.","journal-title":"J Med Econ"},{"key":"3163_CR27","unstructured":"FDA. FDA Offers Guidance to Enhance Diversity in Clinical Trials, Encourage Inclusivity in Medical Product Development. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-offers-guidance-enhance-diversity-clinical-trials-encourage-inclusivity-medical-product. Accessed 23 Nov 2024."},{"key":"3163_CR28","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.14309\/ajg.0000000000002753","volume":"119","author":"A Shin","year":"2024","unstructured":"Shin A, Xu H. Healthcare costs of irritable bowel syndrome and irritable bowel syndrome subtypes in the United States. Am J Gastroenterol. 2024;119:1571\u20139.","journal-title":"Am J Gastroenterol"},{"key":"3163_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3111\/13696998.2014.919926","volume":"17","author":"A Guerin","year":"2014","unstructured":"Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. J Med Econ. 2014;17:577\u201386.","journal-title":"J Med Econ"},{"key":"3163_CR30","first-page":"2118","volume":"116","author":"ED Shah","year":"2021","unstructured":"Shah ED, Staller K, Nee J, et al. Evaluating the impact of cost on the treatment algorithm for chronic idiopathic constipation: cost-effectiveness analysis. Am J Gastroenterol. 2021;116:2118\u201327.","journal-title":"Am J Gastroenterol"},{"key":"3163_CR31","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.14309\/ajg.0000000000001687","volume":"117","author":"GS Sayuk","year":"2022","unstructured":"Sayuk GS, Waldman SA, Brenner DM. Mechanisms of action of current pharmacologic options for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Off J Am Coll Gastroenterol ACG. 2022;117:S6\u201313.","journal-title":"Off J Am Coll Gastroenterol ACG"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03163-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03163-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03163-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:56Z","timestamp":1744872656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03163-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3163"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03163-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric Shah: has served as a consultant for Salix, Mahana, Neuraxis, Phathom, Takeda, Ardelyx, Sanofi, and GI Supply. Zachary Baldwin, Yuri Sanchez Gonzalez, Jens Kort, and Tsung-Ying Lee are employees of AbbVie and may own AbbVie stock or options. Masakazu Ando and Mena Boules are employees of Ironwood Pharmaceuticals, Inc. Steven Champaloux was an employee of Ironwood Pharmaceuticals, Inc. at the time of the study conduct.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective analysis utilized de-identified data from claims data and did not require ethics board approval. AbbVie had a license with MarketScan for use of the database. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}